Skip to content
Virax Biolabs

Innovating Immune Resistance Testing

  • ViraxImmune™
  • Media
  • Leadership
  • Contact
  • Investor Relations
  • ViraxImmune™
  • Media
  • Leadership
  • Contact
  • Investor Relations

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Virax Biolabs’ CEO James Foster Issues Letter to Shareholders

Molecular Diagnostics Adapts to Evolving Diseases (feat. Dr. Tomasz George, CSO)

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances (feat. James Foster, CEO)

Virax Biolabs Introduces Human Papillomavirus (“HPV”) Test Kit

Determining Long Term Immunity May Aid in Understanding Vaccine Efficacy – Interview with Dr. Tomasz George, CSO

by John Parkinson

Virax Biolabs Preparing T-Cell Testing Platform to Provide Consumers With Immune Status Info

by Kelsy Ketchum

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Assessing Adaptive Immune Responses to Viruses to Inform Decisions about Vaccinations with Dr. Tomasz George

By Karen Jagoda

In Every Crisis There Is An Opportunity – Interview with Chief Executive, James Foster

by Tom Hickey

← Previous
Next →

BioCity Glasgow
Bo’Ness Road, Newhouse
Lanarkshire
ML1 5UH
United Kingdom

Quick links

  • Discover ViraxImmune™ Novel PAIS Diagnostic Development
  • Custom Immunology Services By Virax Biolabs
  • Terms and Conditions
  • News And Media Updates From Virax Biolabs
  • Meet Virax Biolabs’ Leadership Team and Advisory Board
  • Contact
  • Investor Relations
  • Discover ViraxImmune™ Novel PAIS Diagnostic Development
  • Custom Immunology Services By Virax Biolabs
  • Terms and Conditions
  • News And Media Updates From Virax Biolabs
  • Meet Virax Biolabs’ Leadership Team and Advisory Board
  • Contact
  • Investor Relations

Subscribe to Our Newsletter

You can cancel subscription any time

Follow us

Facebook Twitter Linkedin Instagram
© All Rights Reserved, Virax Biolabs 2026 | Privacy Policy | Terms of Service